In this episode, host Allison Brashear, MD, MBA, speaks with Ajay Chaudhuri, MBBS, and Kathleen E. Bethin, MD, PhD, about the latest science on obesity and metabolic disease, erasing stigma and the potential of new GLP-1 medications.
Mahmoud Nassar, MD, PhD, a trainee in the endocrinology, diabetes and metabolism fellowship program at the Jacobs School of Medicine and Biomedical Sciences, received several prestigious outstanding research awards at the American College of Gastroenterology (ACG) 2024 annual meeting.
GLP-1RA medications, such as those with brand names of Ozempic and Victoza, don’t put patients with a history of pancreatitis at increased risk for pancreatitis, and they may actually lower their risk.
Three residents, a fellow and two generalist scholars received honors for outstanding poster presentations at the 26th Annual Graduate Medical Education Research Day.
Treating newly diagnosed Type 1 diabetes patients with semaglutide (trade names Ozempic, Wegovy and Rybelsus) may drastically reduce or even eliminate their need for injected insulin.
Paresh Dandona, MD, PhD, has been honored with a Lifetime Achievement Award from the Androgen Society for recognition of his continuing and progressive contributions to the study of hypogonadotropic hypogonadism and its treatment with testosterone, which led to several novel discoveries.
Paresh Dandona, MD, PhD, SUNY Distinguished Professor of medicine in the Division of Endocrinology, Diabetes and Metabolism, is co-author on a study that shows low doses of pioglitazone used to treat diabetes in patients with insulin resistance may be preferable. In this study, patients had a history of previous stroke or transient ischemic attack (TIA).
